TScan Therapeutics, Inc.
TCRX
$1.60
-$0.12-6.98%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -42.91% | -26.01% | -27.99% | -33.28% | -34.73% |
| Total Depreciation and Amortization | -23.37% | -15.96% | -10.74% | -5.97% | 4.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 53.59% | 3.76% | 6.41% | 1.43% | 1.70% |
| Change in Net Operating Assets | -71.29% | -127.22% | 372.41% | 343.27% | 272.10% |
| Cash from Operations | -80.62% | -99.95% | 9.39% | 4.18% | 7.74% |
| Capital Expenditure | -21.58% | 15.98% | -12.95% | 33.52% | 25.54% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.32% | -24.32% | -- | -- | -- |
| Cash from Investing | 13.41% | -21.77% | -1,765.12% | -424.23% | -1,338.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -18.75% | -19.92% | -22.76% | 18,202.10% | 13,182.52% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 71.44% | 39.09% | 39.24% | 28,593.21% | 28,593.21% |
| Cash from Financing | 54.13% | 20.34% | -2.00% | 363.65% | 361.38% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 240.16% | -223.46% | -59.97% | 199.28% | 132.21% |